Rizatriptan Benzoate Tablet
Product Images NDC 57237-087

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 57237-087). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response by 2 hours post-dose in pooled studies for Rizatriptan Benzoate 5 mg, 10 mg, and placebo. The graph plots estimated probability of response (0-100%) on the y-axis against hours post-dose (0 to 2) on the x-axis, illustrating higher response probability with Rizatriptan Benzoate compared to placebo.*

FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

A Kaplan-Meier plot showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets (5 mg and 10 mg) or other medication for migraines over 24 hours after the initial dose, compared to placebo. The plot tracks probability versus hours post-dose, based on pooled data from four placebo-controlled clinical trials.*

FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig3)

A line graph titled 'Observed Percentage of Patients Reporting No Headache Pain by 2 Hours Post-Dose in Study 7' comparing Rizatriptan Benzoate Orally Disintegrating Tablets versus placebo. The x-axis represents hours post stage 2 dose (0.5 to 2.0 hours) and the y-axis represents percent of patients (0 to 100%). The graph shows a higher percentage of patients reporting no headache pain over time with Rizatriptan Benzoate compared to placebo, with error bars indicating 95% confidence intervals.*

FDA Label Image

Package Label-principal Display Panel (5 mg 18 Tablets (3 Blister Cards of 6 Tablets each))

The image shows the packaging label for Rizatriptan Benzoate Tablets, USP, 5 mg oral tablets by Rising Pharma Holdings, Inc. The label indicates a package size of 12 tablets, arranged as 4 blister cards with 3 tablets each. It includes dosing information notes, storage instructions, a barcode, and distribution details by Rising Health, LLC.*

FDA Label Image

Package Label-principal Display Panel -10 mg 18 Tablets (3 Blister Cards Of 6 Tablets Each) (Rizatriptan Fig5)

Packaging label for Rizatriptan Benzoate Tablets, USP 10 mg, oral tablet form by Rising Pharma Holdings, Inc. The label indicates 12 tablets (4 blister cards of 3 tablets each) with prescription-only status. The label includes storage instructions and dosage form details, along with distribution information by Rising Health, LLC, Saddle Brook, NJ.*

FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical structure diagram of Rizatriptan Benzoate, showing the molecular arrangement of its atoms and bonds as represented in a line drawing format with distinct ring structures and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.